. 2022 Jun 28;61(SI2):SI143-SI150.

doi: 10.1093/rheumatology/keac249.

Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey

Lisa G Rider¹, Christine G Parks², Jesse Wilkerson³, Adam I Schiffenbauer¹, Richard K Kwok⁴, Payam Noroozi Farhadi¹, Sarvar Nazir¹, Rebecca Ritter³, Emily Sirotich⁵, Kevin Kennedy⁶, Maggie J Larche⁵, Mitchell Levine⁶, Sebastian E Sattui⁷, Jean W Liew⁸, Carly O Harrison⁹, Tarin T Moni¹⁰, Aubrey K Miller⁴, Michael Putman¹¹, Jonathan Hausmann¹², Julia F Simard¹³, Jeffrey A Sparks¹⁴, Frederick W Miller¹; COVID-19 Global Rheumatology Alliance Vaccine Survey Group

Collaborators, Affiliations

Collaborators

COVID-19 Global Rheumatology Alliance Vaccine Survey Group:
Akpabio A Akpabio, Deshire Alpizar-Rodriguez, Francis Berenbaum, Inita Bulina, Richard Conway, Aman Dev Singh, Eimear Duff, Karen Durrant, Tamer A Gheita, Catherine L Hill, Richard Howard, Bimba F Hoyer, Evelyn Hsieh, Lina El Kibbi, Adam Kilian, Alfred H J Kim, David Liew, Chieh Lo, Bruce Miller, Serena Mingolla, Michal Nudel, Candace A Palmerlee, Jasvinder A Singh, Namrata Singh, Manuel F Ugarte-Gil, John Wallace, Kristen J Young, Suleman Bhana, Wendy Costello, Rebecca Grainger, Pedro M Machado, Philip C Robinson, Paul Sufka, Zachary S Wallace, Jinoos Yazdany, Gary Foster, Lehana Thabane, Saskya Angevare, Richard P Beesley, Eugenia Chock, Berk Degirmenci, Christele Felix, Shangyi Jin, Elsa Mateus, Andrea Peirce, Esra Sari, Robert Tseng, Leslie Wang, Erick Adrian Zamora

Affiliations

¹ Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Bethesda, MD.
² Epidemiology Branch, NIEHS, NIH, Research Triangle Park.
³ Social Scientific Systems, Durham.
⁴ Office of the Director, NIEHS, NIH, Research Triangle Park, NC, USA.
⁵ Department of Medicine, McMaster University.
⁶ Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada.
⁷ Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
⁸ Section of Rheumatology, Boston University School of Medicine, Boston, MA.
⁹ LupusChat, New York, NY, USA.
¹⁰ Department of Biochemistry and Biomedical Sciences, McMaster University Faculty of Science, Hamilton, ON, Canada.
¹¹ Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI.
¹² Program in Rheumatology, Boston Children's Hospital, Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA.
¹³ Department of Epidemiology and Population Health, and Immunology and Rheumatology (Department of Medicine), Stanford University School of Medicine.
¹⁴ Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 35460240
PMCID: PMC9248066
DOI: 10.1093/rheumatology/keac249

Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey

Lisa G Rider et al. Rheumatology (Oxford). 2022.

. 2022 Jun 28;61(SI2):SI143-SI150.

doi: 10.1093/rheumatology/keac249.

Authors

Collaborators

COVID-19 Global Rheumatology Alliance Vaccine Survey Group:
Akpabio A Akpabio, Deshire Alpizar-Rodriguez, Francis Berenbaum, Inita Bulina, Richard Conway, Aman Dev Singh, Eimear Duff, Karen Durrant, Tamer A Gheita, Catherine L Hill, Richard Howard, Bimba F Hoyer, Evelyn Hsieh, Lina El Kibbi, Adam Kilian, Alfred H J Kim, David Liew, Chieh Lo, Bruce Miller, Serena Mingolla, Michal Nudel, Candace A Palmerlee, Jasvinder A Singh, Namrata Singh, Manuel F Ugarte-Gil, John Wallace, Kristen J Young, Suleman Bhana, Wendy Costello, Rebecca Grainger, Pedro M Machado, Philip C Robinson, Paul Sufka, Zachary S Wallace, Jinoos Yazdany, Gary Foster, Lehana Thabane, Saskya Angevare, Richard P Beesley, Eugenia Chock, Berk Degirmenci, Christele Felix, Shangyi Jin, Elsa Mateus, Andrea Peirce, Esra Sari, Robert Tseng, Leslie Wang, Erick Adrian Zamora

Affiliations

¹ Environmental Autoimmunity Group, Clinical Research Branch, National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health (NIH), Bethesda, MD.
² Epidemiology Branch, NIEHS, NIH, Research Triangle Park.
³ Social Scientific Systems, Durham.
⁴ Office of the Director, NIEHS, NIH, Research Triangle Park, NC, USA.
⁵ Department of Medicine, McMaster University.
⁶ Department of Health Research Methods, Evidence and Impact (HEI), McMaster University, Hamilton, ON, Canada.
⁷ Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh, PA.
⁸ Section of Rheumatology, Boston University School of Medicine, Boston, MA.
⁹ LupusChat, New York, NY, USA.
¹⁰ Department of Biochemistry and Biomedical Sciences, McMaster University Faculty of Science, Hamilton, ON, Canada.
¹¹ Division of Rheumatology, Medical College of Wisconsin, Milwaukee, WI.
¹² Program in Rheumatology, Boston Children's Hospital, Division of Rheumatology and Clinical Immunology, Beth Israel Deaconess Medical Center, and Harvard Medical School, Boston, MA.
¹³ Department of Epidemiology and Population Health, and Immunology and Rheumatology (Department of Medicine), Stanford University School of Medicine.
¹⁴ Division of Rheumatology, Immunology, Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

PMID: 35460240
PMCID: PMC9248066
DOI: 10.1093/rheumatology/keac249

Abstract

Objective: To examine the frequency of, and risk factors for, disease flare following COVID-19 vaccination in patients with systemic rheumatic disease (SRD).

Methods: An international study was conducted from 2 April to 16 August 2021, using an online survey of 5619 adults with SRD for adverse events following COVID-19 vaccination, including flares of disease requiring a change in treatment. We examined risk factors identified a priori based on published associations with SRD activity and SARS-CoV-2 severity, including demographics, SRD type, comorbidities, vaccine type, cessation of immunosuppressive medications around vaccination and history of reactions to non-COVID-19 vaccines, using multivariable logistic regression.

Results: Flares requiring a change in treatment following COVID-19 vaccination were reported by 4.9% of patients. Compared with rheumatoid arthritis, certain SRD, including systemic lupus erythematosus (OR 1.51, 95% CI 1.03, 2.20), psoriatic arthritis (OR 1.95, 95% CI 1.20, 3.18) and polymyalgia rheumatica (OR 1.94, 95% CI 1.08, 2.48) were associated with higher odds of flare, while idiopathic inflammatory myopathies were associated with lower odds for flare (OR 0.54, 95% CI 0.31-0.96). The Oxford-AstraZeneca vaccine was associated with higher odds of flare relative to the Pfizer-BioNTech vaccine (OR 1.44, 95% CI 1.07, 1.95), as were a prior reaction to a non-COVID-19 vaccine (OR 2.50, 95% CI 1.76, 3.54) and female sex (OR 2.71, 95% CI 1.55, 4.72).

Conclusion: SRD flares requiring changes in treatment following COVID-19 vaccination were uncommon in this large international study. Several potential risk factors, as well as differences by disease type, warrant further examination in prospective cohorts.

Keywords: COVID-19; disease flare; systemic rheumatic diseases; vaccine.

Published by Oxford University Press on behalf of the British Society for Rheumatology 2022. This work is written by US Government employees and is in the public domain in the US.

PubMed Disclaimer

References

1. Dagan N, Barda N, Kepten E. et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med 2021;384:1412–23. - PMC - PubMed
1. Fagni F, Simon D, Tascilar K. et al. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021;3:e724–36. - PMC - PubMed
1. Sattui SE, Liew JW, Kennedy K. et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. RMD Open 2021;7:e001814. - PMC - PubMed
1. Felten R, Kawka L, Dubois M. et al. Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. Lancet Rheumatol 2021;3:e613–5. - PMC - PubMed
1. Connolly CM, Ruddy JA, Boyarsky BJ. et al. Disease flare and reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination. Arthritis Rheumatol 2022;74:28–32. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

Grants and funding

HHSN273201600002I/ES/NIEHS NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey

Collaborators

Affiliations

Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey

Authors

Collaborators

Affiliations

Abstract

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous